Vivos Therapeutics, Inc. Operating Expenses
Vivos Therapeutics, Inc. (VVOS) reported Operating Expenses of $7.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Vivos Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $7.78M, a 11.51% increase year-over-year.
- Vivos Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $9.67M, a 78.26% increase year-over-year.
- Vivos Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $9.37M, a 91.11% increase year-over-year.
- Vivos Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $8.67M, a 74.15% increase year-over-year.
- Vivos Therapeutics, Inc. operating expenses for fiscal 2025 was $30.44M, a 50.75% increase from fiscal 2024.
- Vivos Therapeutics, Inc. operating expenses for fiscal 2024 was $20.19M, a 21.03% decline from fiscal 2023.
- Vivos Therapeutics, Inc. operating expenses for fiscal 2023 was $25.57M, a 27.06% decline from fiscal 2022.
- Vivos Therapeutics, Inc. operating expenses for fiscal 2022 was $35.05M, a 6.26% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.78M 10-Q · filed 2026-08-14 | $17.45M 10-Q · filed 2026-08-14 | $26.82M derived: sum of 3 quarters · filed 2026-08-14 | $35.49M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $9.67M 10-Q · filed 2026-05-20 | $19.04M derived: sum of 2 quarters · filed 2026-05-20 | $27.71M derived: sum of 3 quarters · filed 2026-05-20 | $34.69M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $18.04M derived: sum of 2 quarters · filed 2026-04-15 | $25.02M derived: sum of 3 quarters · filed 2026-08-14 | $30.44M 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | $8.67M 10-Q · filed 2025-11-19 | $15.65M derived: sum of 2 quarters · filed 2026-08-14 | $21.07M 10-Q · filed 2025-11-19 | $25.98M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $6.97M 10-Q · filed 2026-08-14 | $12.40M 10-Q · filed 2026-08-14 | $17.30M derived: sum of 3 quarters · filed 2026-08-14 | $22.28M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $5.43M 10-Q · filed 2026-05-20 | $10.33M derived: sum of 2 quarters · filed 2026-05-20 | $15.31M derived: sum of 3 quarters · filed 2026-05-20 | $19.90M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $9.88M derived: sum of 2 quarters · filed 2026-04-15 | $14.47M derived: sum of 3 quarters · filed 2026-04-15 | $20.19M 10-K · filed 2026-04-15 | ||||
| 2024-09-30 | $4.98M 10-Q · filed 2025-11-19 | $9.57M derived: sum of 2 quarters · filed 2025-11-19 | $15.29M 10-Q · filed 2025-11-19 | $21.51M derived: sum of 4 quarters · filed 2025-11-19 | ||||
| 2024-06-30 | $4.59M 10-Q · filed 2025-08-19 | $10.31M 10-Q · filed 2025-08-19 | $16.53M derived: sum of 3 quarters · filed 2025-08-19 | $21.92M derived: sum of 4 quarters · filed 2025-08-19 | ||||
| 2024-03-31 | $5.72M 10-Q · filed 2025-05-15 | $11.94M derived: sum of 2 quarters · filed 2025-05-15 | $17.33M derived: sum of 3 quarters · filed 2025-05-15 | $23.95M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $11.61M derived: sum of 2 quarters · filed 2025-03-31 | $18.22M derived: sum of 3 quarters · filed 2025-03-31 | $25.57M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $5.39M 10-Q · filed 2024-11-14 | $12.00M derived: sum of 2 quarters · filed 2024-11-14 | $19.34M 10-Q · filed 2024-11-14 | $27.79M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $6.62M 10-Q · filed 2024-08-14 | $13.96M 10-Q · filed 2024-08-14 | $22.40M derived: sum of 3 quarters · filed 2024-08-14 | $30.31M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $7.34M 10-Q · filed 2024-05-14 | $15.79M derived: sum of 2 quarters · filed 2024-07-30 | $23.69M derived: sum of 3 quarters · filed 2024-07-30 | $33.24M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-12-31 | $8.45M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-07-30 | $16.35M derived: sum of 2 quarters · filed 2024-07-30 | $25.90M derived: sum of 3 quarters · filed 2024-07-30 | $35.05M 10-K/A · filed 2024-07-30 | ||||
| 2022-09-30 | $7.90M 10-Q · filed 2023-11-14 | $17.45M derived: sum of 2 quarters · filed 2023-11-14 | $26.60M 10-Q · filed 2023-11-14 | $37.16M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $9.55M 10-Q · filed 2023-08-16 | $18.70M 10-Q · filed 2023-08-16 | $29.26M derived: sum of 3 quarters · filed 2023-08-16 | $37.95M derived: sum of 4 quarters · filed 2023-08-16 | ||||
| 2022-03-31 | $9.19M 10-Q · filed 2023-06-08 | $19.71M derived: sum of 2 quarters · filed 2023-06-08 | $28.39M derived: sum of 3 quarters · filed 2023-06-08 | $36.08M derived: sum of 4 quarters · filed 2023-06-08 | ||||
| 2021-12-31 | $10.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $19.20M derived: sum of 2 quarters · filed 2023-03-30 | $26.89M derived: sum of 3 quarters · filed 2023-03-30 | $32.99M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $8.69M 10-Q · filed 2022-12-20 | $8.69M 10-Q · filed 2021-11-15 | $16.37M derived: sum of 2 quarters · filed 2022-12-20 | $22.47M 10-Q · filed 2022-12-20 | $22.47M 10-Q · filed 2021-11-15 | $31.40M derived: sum of 4 quarters · filed 2022-12-20 | ||
| 2021-06-30 | $7.68M 10-Q · filed 2022-12-20 | $7.69M 10-Q · filed 2021-08-12 | $13.78M 10-Q · filed 2022-12-20 | $13.78M 10-Q · filed 2021-08-12 | $22.72M derived: sum of 3 quarters · filed 2022-12-20 | $27.12M derived: sum of 4 quarters · filed 2022-12-20 | ||
| 2021-03-31 | $6.10M 10-Q/A · filed 2022-11-25 | $6.10M 10-Q · filed 2021-05-17 | $15.03M derived: sum of 2 quarters · filed 2022-11-25 | $19.43M derived: sum of 3 quarters · filed 2022-11-25 | $23.58M derived: sum of 4 quarters · filed 2022-11-25 | |||
| 2020-12-31 | $8.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $13.34M derived: sum of 2 quarters · filed 2022-03-31 | $17.48M derived: sum of 3 quarters · filed 2022-03-31 | $22.45M 10-K · filed 2022-03-31 | $22.45M 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $4.40M 10-Q · filed 2021-11-15 | $8.54M derived: sum of 2 quarters · filed 2021-11-15 | $13.52M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $4.14M 10-Q · filed 2021-08-12 | $9.12M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $4.97M 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | $19.23M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |